newsfilter
← Latest News
GlobeNewswire·

MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study

MIRA
  • MIRA Pharmaceuticals announced positive results from a 21-day preclinical study of oral MIRA-55 in a chronic inflammatory pain model, supporting advancement toward an Investigational New Drug submission.
  • Once-daily oral MIRA-55 significantly reduced mechanical & thermal pain hypersensitivity (p < 0.001) from the lowest dose tested.
  • Pain relief effects from MIRA-55 were comparable in magnitude to celecoxib at higher doses with no statistically significant differences observed.
  • Efficacy was maintained throughout the three-week study without evidence of tolerance or adverse clinical signs.
  • The study included 72 rats of both sexes, showing consistent pain-relieving activity across male & female animals.
  • MIRA-55 reduced inflammation-associated paw swelling to a similar extent as celecoxib.
  • MIRA-55 is a next-generation synthetic cannabinoid analog designed to modulate pain & inflammation pathways while minimizing psychoactive effects.
  • The U.S. Drug Enforcement Administration has determined that MIRA-55 is not a controlled substance.
  • The company plans to submit an IND for MIRA-55 in the first quarter of 2027, subject to completing remaining preclinical & regulatory activities.
  • Additional tissue analyses are underway to evaluate inflammatory cytokines & molecular markers to further define the mechanism of action.
  • Chairman & CEO Erez Aminov stated the company is building a differentiated pain franchise with MIRA-55 for inflammatory pain & Ketamir-2 for neuropathic pain.